{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:14:43Z","timestamp":1790154883024,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Valneva Austria GmbH"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.tmaid.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T20:06:04Z","timestamp":1521144364000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO\u00ae, JESPECT\u00ae) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study"],"prefix":"10.1016","volume":"22","author":[{"given":"Tomas","family":"Jelinek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Cromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob P.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lessans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Gherardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.F.","family":"Hagmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena H.","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Kiermayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kadlecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Eder-Lingelbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Taucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin L.","family":"Dubischar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.tmaid.2018.03.003_bib1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.68.4.405","article-title":"Japanese encephalitis","volume":"68","author":"Solomon","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.tmaid.2018.03.003_bib2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2471\/BLT.10.085233","article-title":"Estimated global incidence of Japanese encephalitis: a systematic review","volume":"89","author":"Campbell","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"9109","key":"10.1016\/j.tmaid.2018.03.003_bib3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(97)07509-0","article-title":"Poliomyelitis-like illness due to Japanese encephalitis virus","volume":"351","author":"Solomon","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tmaid.2018.03.003_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000114","article-title":"Measuring the burden of neglected tropical diseases: the global burden of disease framework","volume":"1","author":"Mathers","year":"2007","journal-title":"PLoS Neglected Trop Dis"},{"issue":"20","key":"10.1016\/j.tmaid.2018.03.003_bib5","first-page":"664","article-title":"MMWR Morbidity and mortality weekly report","volume":"60","author":"Update on Japanese encephalitis vaccine for children: United States, May 2011","year":"2011"},{"issue":"39","key":"10.1016\/j.tmaid.2018.03.003_bib6","first-page":"413","article-title":"Releve epidemiologique hebdomadaire","volume":"88","author":"Haemophilus influenzae type b (Hib) Vaccination Position Paper - July 2013","year":"2013"},{"issue":"RR-1","key":"10.1016\/j.tmaid.2018.03.003_bib7","first-page":"1","article-title":"Japanese encephalitis vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR recommendations and reports","volume":"59","author":"Fischer","year":"2010","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"issue":"5","key":"10.1016\/j.tmaid.2018.03.003_bib8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4269\/ajtmh.2010.09-0676","article-title":"Japanese encephalitis in travelers from non-endemic countries, 1973-2008","volume":"82","author":"Hills","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.tmaid.2018.03.003_bib9","series-title":"Vaccines","first-page":"201","article-title":"Japanese encephaltis vaccines","author":"Halstead","year":"2012"},{"key":"10.1016\/j.tmaid.2018.03.003_bib10","author":"European Medicines Agency IXIARO"},{"key":"10.1016\/j.tmaid.2018.03.003_bib11","author":"U.S Food and Drug administration IXIARO"},{"issue":"3","key":"10.1016\/j.tmaid.2018.03.003_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Kaltenbock","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.tmaid.2018.03.003_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/INF.0000000000001623","article-title":"Safety of the inactivated Japanese encephalitis virus vaccine IXIARO in children: an open-label, randomized, active-controlled, phase 3 study","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.tmaid.2018.03.003_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/INF.0000000000001615","article-title":"Immunogenicity of the inactivated Japanese encephalitis virus vaccine IXIARO in children from a Japanese encephalitis virus-endemic region","volume":"36","author":"Dubischar","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.tmaid.2018.03.003_bib15","series-title":"Division of AIDS, table for grading the severity of adult and pediatric adverse events. Version 1.0","author":"National Institute of Allergy and Infectious Diseases","year":"2004"},{"issue":"9602","key":"10.1016\/j.tmaid.2018.03.003_bib16","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"issue":"45","key":"10.1016\/j.tmaid.2018.03.003_bib17","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.tmaid.2018.03.003_bib18","first-page":"2689","article-title":"Review on flavivirus vaccine development","volume":"vol. 23","author":"Hombach","year":"2005"},{"key":"10.1016\/j.tmaid.2018.03.003_bib19","series-title":"BMJ","article-title":"Statistics with confidence","author":"Altman","year":"2000"},{"issue":"39","key":"10.1016\/j.tmaid.2018.03.003_bib20","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1016\/j.vaccine.2010.07.040","article-title":"Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.tmaid.2018.03.003_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.tmaid.2018.03.003_bib22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/QCO.0b013e32833c1d01","article-title":"Japanese encephalitis: update on vaccines and vaccine recommendations","volume":"23","author":"Wilder-Smith","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.tmaid.2018.03.003_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40794-017-0057-x","article-title":"The changing epidemiology of Japanese encephalitis and New data: the implications for New recommendations for Japanese encephalitis vaccine","volume":"3","author":"Connor","year":"2017","journal-title":"Tropical diseases, travel medicine and vaccines"},{"issue":"33","key":"10.1016\/j.tmaid.2018.03.003_bib24","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1016\/j.vaccine.2009.05.034","article-title":"Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study","volume":"27","author":"Kaltenbock","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.tmaid.2018.03.003_bib25","series-title":"Abstract FC2.04. Conference of the international society of travel medicine","article-title":"Antibody persistence in children from JE non-endemic and JE endemic countries and after a booster dose of inactivated Japanese encephalitis vaccine","author":"Dubischar-Kastner","year":"2015"},{"issue":"38","key":"10.1016\/j.tmaid.2018.03.003_bib26","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1016\/j.vaccine.2016.07.029","article-title":"Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO(R) in elderly subjects: open-label, uncontrolled, multi-center, phase 4 study","volume":"34","author":"Cramer","year":"2016","journal-title":"Vaccine"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893918300462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893918300462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:03:07Z","timestamp":1761487387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893918300462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":26,"alternative-id":["S1477893918300462"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2018.03.003","relation":{},"ISSN":["1477-8939"],"issn-type":[{"value":"1477-8939","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO\u00ae, JESPECT\u00ae) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}